Anixa Biosciences (ANIX) Non Operating Interest Expenses (2013 - 2020)
Anixa Biosciences' (ANIX) quarterly Non Operating Interest Expenses came in at $148084.0 in Q3 2020, up 706.38% on a YoY basis from $18364.0 in Q3 2019, and up 706.38% quarter-over-quarter from $18364.0 in Q3 2019.
Powered by 
Analysis
Anixa Biosciences (ANIX) Non Operating Interest Expenses (2013 - 2020) Analysis & Trends
Anixa Biosciences (ANIX) has reported Non Operating Interest Expenses for 7 consecutive years, with $148084.0 the latest figure, recorded in Q3 2020.
- For the quarter ending Q3 2020, Non Operating Interest Expenses rose 706.38% year-over-year to $148084.0; the trailing twelve-month figure through Jul 2020 stood at $295877.0 (down 8.54% YoY), and the FY2017 full-year result was $500455.0, down 3.75% from the prior year.
- Non Operating Interest Expenses improved to $148084.0 in Q3 2020 per ANIX's latest filing, from $18364.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $195299.0 in Q1 2017 and bottomed at $18364.0 in Q3 2019.
- Historically, Non Operating Interest Expenses has averaged $118684.9 across 4 years, with a median of $129668.5 in 2016.
- The sharpest annual moves came in 2017 and 2020: Non Operating Interest Expenses slumped 57.75% in 2017, then surged 706.38% in 2020.
- Over 4 years, Non Operating Interest Expenses stood at $136708.0 in 2016, then sank by 57.75% to $57762.0 in 2017, then tumbled by 68.21% to $18364.0 in 2019, then soared by 706.38% to $148084.0 in 2020.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $148084.0, $18364.0, and $57762.0 for Q3 2020, Q3 2019, and Q4 2017 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 4.00 Bn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -5.80 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 14.37 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 2.95 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | - |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 160,000.00 |
| 10 | Anixa Biosciences | 104.14 Mn | 102.89 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2020 | 148,084.00 |
| Jul 31, 2019 | 18,364.00 |
| Oct 31, 2017 | 57,762.00 |
| Jul 31, 2017 | 71,667.00 |
| Apr 30, 2017 | 175,727.00 |
| Jan 31, 2017 | 195,299.00 |
| Oct 31, 2016 | 136,708.00 |
| Jul 31, 2016 | 132,357.00 |
| Apr 30, 2016 | 126,980.00 |
| Jan 31, 2016 | 123,901.00 |
| Oct 31, 2015 | 118,127.00 |
| Jul 31, 2015 | 115,981.00 |
| Apr 30, 2015 | 108,612.00 |
| Jan 31, 2015 | 109,186.00 |
| Oct 31, 2014 | 181,576.00 |
| Jul 31, 2014 | 280,913.00 |
| Apr 30, 2014 | 422,463.00 |
| Jan 31, 2014 | 378,665.00 |
| Apr 30, 2013 | 835,458.00 |
| Jan 31, 2013 | 22,195.00 |